SCN8A相关疾病的自然史解析
该研究整合82例SCN8A相关疾病患者的电子病历数据,并与2833例已知或推测遗传性癫痫患者比较,重建其纵向自然史。SCN8A相关疾病在1岁时双侧强直-阵挛发作的比值比超过10倍,功能获得(GOF)变异携带者早期癫痫和发育迟缓风险高,复发变异有独特发作表型,钠通道阻滞剂对GOF及未功能表征变异有效。
要点
- SCN8A相关疾病1岁时双侧强直-阵挛发作风险显著高于其他遗传性癫痫(OR 10.56)。
- GOF变异携带者6个月癫痫风险(OR 4.71)和3个月全面发育迟缓风险(OR 5.67)增高。
- 钠通道阻滞剂对GOF变异及未功能表征变异携带者的SCN8A癫痫有效。
核心结论
- SCN8A相关疾病以婴儿期频繁双侧强直-阵挛发作为特征,GOF变异携带者早期癫痫和发育特征突出,复发变异具有独特发作表型。
研究设计与样本
- 研究整合82例SCN8A相关疾病患者的电子病历数据,并与2833例已知或推测遗传性癫痫患者队列比较,重建自然史。
主要发现
- 复发p.Arg850Gln变异携带者6个月婴儿痉挛更常见,p.Arg1872Trp/Gln/Leu热点变异携带者新生儿癫痫更常见。
临床怎么用
- 钠通道阻滞剂对GOF变异携带者及未功能表征变异携带者的SCN8A癫痫有效,提示许多未研究变异可能具有GOF机制。
- 复发p.Gly1475Arg变异携带者5岁后活动性癫痫更常见,p.Arg1617Gln变异携带者儿童后期局灶性发作更突出,p.Asn1877Ser变异携带者全面性发作更突出。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: SCN8A-related disorders encompass a range of neurodevelopmental and epilepsy phenotypes. However, despite representing one of the most common epilepsy-associated channelopathies, its longitudinal phenotypes remain largely uncharacterized. METHODS: In this study, we harmonized electronic medical record data from 82 individuals with SCN8A-related disorders to reconstruct the natural history of the disorder in comparison with a cohort of 2,833 individuals with known or presumed genetic epilepsies. RESULTS: Compared with the cohort of other known or presumed genetic epilepsies, those with SCN8A-related disorders (mean age = 8.3 years, 52% female) had >10-fold odds of bilateral tonic-clonic seizures as early as at 1 year (p = 1.70 × 10-14, OR 10.56, CI 5.85-18.90). Individuals carrying gain-of-function (GOF) SCN8A variants had particularly high seizure risk at 6 months (p = 0.007/pthreshold = 4.25 × 10-4, OR 4.71, CI 1.36-21.25) and an increased risk of global developmental delay as early as at 3 months (p = 0.002/pthreshold = 4.72 × 10-5, OR 5.67, CI 1.74-20.23) when compared with the broader SCN8A cohort. Individuals with loss-of-function variants were more likely to have atypical absence seizures, most prominently at 4.25 years (p = 0.013/pthreshold = 7.08 × 10-4, OR 32.71, CI 1.44-2,193.51). Compared with the broader SCN8A cohort, individuals with the recurrent p.Arg850Gln variant were more likely to have infantile spasms at 6 months and those with variants at the p.Arg1872Trp/Gln/Leu hotspot were more likely to have neonatal seizures. Individuals with the recurrent p.Gly1475Arg variant were more likely to have active epilepsy after 5 years of age. In later childhood, focal seizures were more prominent in individuals with the recurrent p.Arg1617Gln variant while generalized-onset seizures were more prominent with the p.Asn1877Ser variant. We also established the effectiveness of sodium channel blockers in managing SCN8A epilepsy in individuals carrying GOF variants and those whose variants have not been functionally characterized, suggesting that many unstudied SCN8A variants may have GOF mechanisms. DISCUSSION: SCN8A-related disorders distinguish themselves from other genetic epilepsies by the frequent bilateral tonic-clonic seizures in infancy, prominent early epileptic and developmental features in GOF variant carriers, and unique seizure phenotypes in those with recurrent variants. Our study provides a longitudinal perspective on SCN8A-related disorders, paving the way for future precision medicine approaches.
引用
- Magielski JH, Cohen S, Kaufman MC, et al. Deciphering the Natural History of SCN8A-Related Disorders. Neurology. 2025. PMID: 40228184. doi:10.1212/WNL.0000000000213533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。